KCM
ADMS

Kornitzer Capital Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Kornitzer Capital Management’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-189,205
Closed -$1.62M – 499
2018
Q4 		$1.62M Sell
189,205
-170,880
-47% -$2.22M 0.03% 329
2018
Q3 		$7.21M Buy
360,085
+41,195
+13% +$967K 0.11% 222
2018
Q2 		$8.24M Buy
318,890
+143,535
+82% +$3.97M 0.14% 201
2018
Q1 		$4.19M Buy
+175,355
New +$5.53M 0.07% 256

Other funds holding ADMS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Kornitzer Capital Management's ADMS Position: Q1 2019 in Review

Kornitzer Capital Management sold out of Adamas Pharmaceuticals (ADMS) in Q1 2019, closing a stake of 189,205 shares — an estimated $1.62M sold.

Kornitzer Capital Management first reported a position in ADMS in Q1 2018 and held it in 4 quarters. The position peaked at $8.24M in Q2 2018. 99 funds tracked by Wall St. Rank hold ADMS as of Q1 2019.

  • Kornitzer Capital Management reported no remaining Adamas Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Kornitzer Capital Management sold 189,205 Adamas Pharmaceuticals shares in Q1 2019, an estimated $1.62M.
  • Kornitzer Capital Management first reported a position in Adamas Pharmaceuticals in Q1 2018 and held it in 4 quarters.
  • Kornitzer Capital Management's Adamas Pharmaceuticals position peaked at $8.24M in Q2 2018.
  • 99 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q1 2019.

Based on Kornitzer Capital Management's 13F filing for Q1 2019, filed 1 May 2019.